Orkambi

DRUG4 trials

Sponsors

Parion Sciences, Children's Hospital of Philadelphia, Assistance Publique - Hôpitaux de Paris, University Hospital, Antwerp

Conditions

Cystic FibrosisHomozygous F508del Mutation

Phase 2

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

CompletedNCT02709109

Parion SciencesCystic Fibrosis

Start: 2016-02-29End: 2017-09-30Updated: 2021-07-29

Phase 4

Functional Respiratory Imaging and Orkambi in CF

TerminatedNCT03956589

University Hospital, AntwerpCystic Fibrosis

Start: 2018-10-01End: 2020-04-01Updated: 2020-04-08

Unknown Phase

Orkambi Treatment in 2 to 5 Year Old Children With CF

CompletedNCT03795363

Children's Hospital of PhiladelphiaCystic Fibrosis

Start: 2019-04-10End: 2021-06-16Updated: 2021-12-02

Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.

CompletedNCT03894657

Assistance Publique - Hôpitaux de ParisCystic Fibrosis, Homozygous F508del Mutation

Start: 2019-12-18End: 2022-05-12Updated: 2026-03-10

Related Papers

First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers

ERJ Open Research2020-12-109 citations